Clinical Trial Update: 17OHP-C Dosing Among Obese Pregnant Women [Phase 3]

View source ↗

Summary

Phase 3 trial assessing 17-hydroxyprogesterone caproate dosing among obese pregnant women; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Birth

Drugs mentioned

• 17 α-hydroxyprogesterone caproate (17α-hydroxyprogesterone caproate)

Snippet

Sponsor: University of South Florida | Conditions: Premature Birth, Absorption; Chemicals | Phase 3 | Status: COMPLETED | Results posted: 2022-01-12